logo
logo
LeMaitre Vascular, Inc.

LeMaitre Vascular, Inc.

NASDAQ•LMAT
CEO: Mr. George W. LeMaitre
セクター: Healthcare
業種: Medical - Instruments & Supplies
上場日: 2006-10-19
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
連絡先情報
63 Second Avenue, Burlington, MA, 01803, United States
781-221-2266
www.lemaitre.com
時価総額
$1.99B
PER (TTM)
37.2
65.7
配当利回り
0.9%
52週高値
$105.55
52週安値
$71.42
52週レンジ
48%
順位23Top 9.4%
5.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 5.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$61.05M+11.36%
直近4四半期の推移

EPS

$0.77+54.00%
直近4四半期の推移

フリーCF

$26.48M+110.58%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Strong Nine-Month Sales Growth Nine-month net sales grew 13% to $185.1M, driven by higher prices and unit volumes shipped to customers.
Net Income Substantially Higher Nine-month net income totaled $42.2M, reflecting a substantial 28.3% increase compared to $32.9M last year.
Gross Margin Expansion Noted Gross margin improved 310 basis points to 71.5% for nine months, aided by ERC receipt of $2.7M.
Operating Cash Flow Doubled Net cash provided by operating activities was $58.1M for nine months, nearly doubling prior year's $28.9M.

リスク要因

Regulatory Approval Vulnerability Products face extensive regulation; approvals, licenses, or clearances risk withdrawal or suspension post-approval.
Global Economic Headwinds Sustained global economic uncertainty and tariffs may negatively affect demand and pressure international gross margins.
Product Liability Exposure Potential product defects or malfunctions could lead to recalls, warning letters, or costly product liability claims.
ERP System Changes New ERP system implementation requires process changes that may affect internal control comparability quarterly.

見通し

Direct Sales Force Growth Strategy focuses on growing direct sales personnel across North America, Europe, and APAC regions replacing distributors.
Capital Return Program Active Board authorized $75.0M common stock repurchase program through February 2026; no repurchases executed yet.
Dividend Rate Increased Quarterly cash dividend increased to $0.20 per share starting in Fiscal Year 2025, up from $0.16.
Continued Product Acquisitions Expect to continue using acquisitions as primary means to penetrate peripheral vascular device market further.

同業比較

売上高 (TTM)

Ardent Health Partners, Inc.ARDT
$6.33B
+10.9%
Acadia Healthcare Company, Inc.ACHC
$3.27B
+4.6%
QuidelOrtho CorporationQDEL
$2.73B
-1.9%

粗利益率 (最新四半期)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
Stoke Therapeutics, Inc.STOK
90.7%
-9.3pp
Inspire Medical Systems, Inc.INSP
86.6%
+1.8pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
TWST$3.01B-39.2-16.6%28.8%
HAE$2.70B15.420.3%49.2%
NHC$2.63B26.010.0%8.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.1%
緩やかな成長
4四半期純利益CAGR
15.8%
収益性の大幅な改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月25日
|
EPS:$0.67
|
売上高:$62.98M
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月7日|
    売上高: $61.05M+11.4%
    |
    EPS: $0.77+54.0%
    予想を上回る
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $64.23M+15.0%
    |
    EPS: $0.61+15.1%
    予想を上回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月8日|
    売上高: $59.87M+12.0%
    |
    EPS: $0.49+14.0%
    予想通り
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月28日|
    売上高: $219.86M+13.6%
    |
    EPS: $1.96+44.1%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月8日|
    売上高: $54.82M+15.6%
    |
    EPS: $0.50+47.1%
    予想を上回る
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月8日|
    売上高: $55.85M+11.4%
    |
    EPS: $0.53+47.2%
    予想を上回る
  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月10日|
    売上高: $53.48M+13.6%
    |
    EPS: $0.43+59.3%
    予想を上回る
  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月29日|
    売上高: $193.48M+19.7%
    |
    EPS: $1.36+44.7%
    予想を上回る